Please assess the completion status of the following clinical trial:

Trial Title: BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 80 years old~2. Planned emergency PCI for acute myocardial infarction (STEMI or NSTEMI) Symptom onset within 12h for STEMI (or within 24 h for patients have unrelieved chest pain, continuous ST elevation or new developed LBBB) Symptom onset within 72h for NSTEMI~3. Avoid to undergoing revascularization for non-culprit vessels within 30 days after index procedure.~4. Provide written informed consent.~Exclusion Criteria:~1. Unsuitable for PCI; treatment by thrombolysis within 72 hours of acute ST-elevation myocardial infarction; left main coronary artery disease; cardiogenic shock.~2. Any anticoagulant agents were used 48 h before randomization.~3. Active bleeding or bleeding constitution, bleeding tendency, including the recent retina or vitreous hemorrhage (1 months), GI or urinary tract hemorrhage (3 months), cerebral hemorrhage (6 months) or cerebral infarction history (3 months), etc.;~4. Other disease may lead to vascular lesions and secondary bleeding factors (such as active gastric ulcer, active ulcerative colitis, intracranial aneurysm, etc.),~5. Deep puncture or major surgery (including eye or brain surgery) within 1 month.~6. Suspicious aortic dissection, pericarditis and subacute bacterial endocarditis.~7. Untreated or uncontrolled hypertension \> 180/110 mmHg.~8. Hemoglobin \< 100 g/L or platelet count \< 100 \* 109 / L.~9. Elevated AST, ALT level higher than three times of the normal upper limit.~10. severe renal insufficiency (eGFR \< 30 mL/min / 1.73 m2).~11. Heparin induced thrombocytopenia.~12. Known allergy to the study drugs and instruments (UFH, bivalirudin, aspirin and clopidogrel, stainless steel, contrast agents, etc.), or those allergic constitution.~13. Pregnancy or lactation.~14. Researchers think that doesn't fit to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bivalirudin (Type: EXPERIMENTAL): Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT\<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
- Heparin monotherapy (Type: ACTIVE_COMPARATOR): 100 IU/kg intravenous bolus. If ACT \<225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
- heparin plus tirofiban (Type: ACTIVE_COMPARATOR): heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.

Based on this trial design, predict the completion outcome and termination type (if applicable).